Japanese experience with second-line chemotherapy with low-dose (60 mg/m) docetaxel in patients with advanced non-small-cell lung cancer

By Mukohara Toru   Takeda Koji   Miyazaki Masaki   Takifuji Nobuhide   Terakawa Kazuhiko   Negoro Shunichi  

Cancer Chemotherapy and Pharmacology, Vol. 48, Iss. 5, 2001-11 ,pp. : 356-360

Springer Publishing Company

Access to resources Recommend Favorite

Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer

By                      

Oncology Letters, Vol. 9, Iss. 6, 2015-01 ,pp. : 2577-2582

Spandidos Publications

Access to resources Recommend Favorite

Docetaxel (taxotere(R)) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer

By Le Chevalier T.   Monnier A.   Douillard J.Y.   Ruffie P.   Sun X.S.   Belli L.   Ibrahim N.   Bougon N.   Berille J.  

European Journal of Cancer, Vol. 34, Iss. 13, 1998-12 ,pp. : 2032-2036

Elsevier

Access to resources Recommend Favorite

Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer

By Kwon Jung   Kim Jung   Lee Jung-Ae   Shin Hyun   Kim Hyo   Song Hun   Jung Joo   Kim Ho   Choi Dae   Kim Hyeong   Park Young-iee   Zang Dae  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 5, 2010-10 ,pp. : 889-897

Springer Publishing Company

Access to resources Recommend Favorite

Triplet chemotherapy combination with cisplatin, gemcitabine and docetaxel in patients with chemotherapynaive advanced non-small cell lung cancer

By          

Oncology Letters, Vol. 5, Iss. 5, 2013-01 ,pp. : 1699-1703

Spandidos Publications

Access to resources Recommend Favorite